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Abstract 
Background 
Osteoporotic hip fractures have become an increasingly common healthcare burden with 
significant morbidity and mortality in the geriatric population. Pharmacological management of 
the underlying osteoporosis is critical. Our objective is to determine the percentage of patients 
older than 65 who receive pharmacologic treatment of osteoporosis at Cabell Huntington 
Hospital within six months after a fragility fracture. 
Methods 
Data was extracted from medical records for patients age 65 or older who sustained a hip fracture 
during June 2013 - March 2015. Patients who received any form of pharmacologic treatment 
within six months after their fractures were identified. All analyses were performed using SAS 
version 9.3 (SAS Institute, Cary, North Carolina). 
Results 
Among the 193 patients who met the inclusion criteria, 26% (n=50) received pharmacologic 
treatment within six months after fracturing versus 74% (n=143) who did not receive any type of 
pharmacologic therapy after the fracture. Female was the predominant gender in pharmacologic 
treatment group (74% vs 71%). Mean age was 81 years old in both groups (81±9 vs 82±8), mean 
BMI was 25 in both groups (25±5 vs 25±6). There was no significant difference in 
pharmacologic management when the patients were stratified according to age group. 
Conclusion 
Patients were pharmacologically undertreated after an osteoporotic hip fracture, regardless of the 
age of fracture presentation. Due to potential benefits of pharmacologic treatment after 
osteoporotic hip fracture, treatment should be initiated prior to discharge, if possible. If this is not 
feasible for the patient, specific and detailed instructions should be given to the patient’s primary 
care physician, or endocrinologist if medically complicated, for initiating therapy and proper 
management of the patient. 
Key Words 
 
Osteoporosis, Hip fracture, Geriatrics, FRAX, PTAF, Pharmacologic management of fractures 
 
Introduction 
 
Due to the growing elderly population, fragility hip fractures have become a common healthcare 
burden. Fragility fracture is defined by the World Health Organization (WHO) as ¨a fracture 
caused by an injury that would be insufficient to fracture a normal bone.¨ According to National 
Osteoporosis Foundation recommendations, any patient age 50 or older who suffers a fragility 
fracture or vertebral fracture can be clinically diagnosed with osteoporosis.2 The lifetime risk of 
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osteoporotic fractures in men and women age 50 or older is 25% and 50%, respectively.1 Most 
patients are not aware that they have osteoporosis until they suffer a fragility fracture (i.e. 
fracture when falling from standing height).2 Osteoporotic hip fractures are a well-established 
source of morbidity and mortality in the geriatric population. They are associated with a 
significant increase in health care service utilization, as well as all forms of post-acute care. This 
includes post-acute hospitalizations, home health care, and physical and occupational therapy. 
Further, patients who were originally community-dwelling have an increased likelihood of living 
in a nursing home after hip fracture.3,4 There is also substantial evidence that prior osteoporotic 
hip fracture results in an increased risk of subsequent fracture.5 The greatest risk appears to be 
soon after fracture, particularly in the first year. Hip fractures are also associated with increased 
mortality rates. The reported one year mortality rate due to hip fracture for women over 50 years 
is 24% and for men up to 49%.1  
 
The acute management of hip fractures is very well established. It includes optimization of 
vitamin D and calcium levels, optimizing the patient for surgery, and surgical repair of the 
fracture. Patients may be discharged as soon as one or two recovery days after surgery. Those 
patients who demonstrate low vitamin D levels are also discharged with vitamin D replacement 
therapy. 
  
The prevention of recurrence via investigation for osteoporosis and initiation of pharmacologic 
treatment after fracture (PTAF) is poorly executed. According to National Osteoporosis 
Foundation recommendations, any patient age 50 or older who suffers an osteoporotic fracture 
should receive PTAF.2 It is crucial to treat these patients pharmacologically in order to medically 
optimize them for functional recovery. Further, FDA-approved medications for osteoporosis 
have been shown to reduce the risk of subsequent osteoporotic fractures.6-12 It is also important 
to initiate PTAF early due to increased risk of subsequent fracture within one year.12 Despite the 
current recommendations, PTAF is often overlooked. 
  
Our objective is to determine the percentage of patients older than 65 who receive PTAF within 
six months after a fragility fracture. It is our hypothesis that this vulnerable population is being 
undertreated. We further hope to determine possible causes of this disparity and propose 
solutions to improve management and patient outcomes. 
  
Methods 
  
Study Design 
 
A retrospective cohort study. SQUIRE 2.0 guideline was used to prepare this quality 
improvement paper.13 
 
Cohort generation 
 
Medical records for patients age 65 or older who sustained hip fracture during June 2013 - March 
2015 were collected from electronic medical records with IRB approval (874559-3). Patients 
with a prior diagnosis of osteoporosis, pathologic hip fracture due to tumor, and those who were 
already on pharmacologic treatment of osteoporosis were excluded. Medications included in 
calculations were bisphosphonates (alendronate, ibandronate, risedronate, zoledronic acid), 
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parathyroid hormone (teriparatide), and RANK ligand inhibitors (denosumab). Vitamin D and 
calcium supplementation were not included in our calculations of pharmacologic treatment. 
Descriptive analysis was performed to extract demographics of our cohort. Age, gender, BMI, 
and whether patients received a DXA scan (dual x-ray absorptiometry) before and after treatment 
were extracted to assess for the difference in treatment with respect to these variables.  
 
Assessment of Risk of Future Fracture 
 
Next, the International Osteoporosis Foundation’s Fracture Risk Assessment Tool (FRAX) was 
used to calculate each patient’s ten-year risk of hip and major osteoporotic fracture using pre-
fracture data. The FRAX tool integrates each patient’s independent risk factors to determine their 
ten-year risk. These risk factors include country of origin, age, gender, BMI, previous fracture, 
parental history of hip fracture, current smoking, use of glucocorticoids, rheumatoid arthritis, 
secondary osteoporosis, alcohol consumption, and, when available, bone mineral density (BMD). 
Patients were excluded from FRAX analysis for the following reasons: age greater than or equal 
to 90 and missing relevant historical information. In clinical practice, patients with greater than 
or equal to a 20% ten-year risk of major osteoporotic fracture or greater than or equal to a 3% 
ten-year risk of hip fracture are treated if they have osteopenia demonstrated by DXA scan. Most 
patients in this study did not have a DXA scan. Therefore FRAX scores will not be used as an 
indication for therapy, but rather, as an assessment of fracture risk.  
 
Statistical Analysis 
 
All categorical variables were compared using Pearson’s χ2 test, while continuous variables were 
compared using t-test. All analyses were performed using SAS version 9.3 (SAS Institute, Cary, 
North Carolina). All p-values were based on 2-sided tests and were considered statistically 
significant when p < 0.05. 
  
Results 
  
Among the 193 patients who met the inclusion criteria, 26% (n=50) received PTAF within six 
months versus 74% (n=143) who did not receive PTAF (Figure 1). Female was the predominant 
gender in both groups (74% vs 71%). Mean age was 81 years old in both groups (81±9 vs 82±8), 
mean BMI was 25 in both groups (25±5 vs 25±6). Demographics and DXA scan histories of the 
193 patients who met the inclusion criteria are presented in Table 1.  
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Figure 1: Out of 193 patients who met inclusion criteria, 50 (26%) received PTAF within six 
months of fracture. 
 
 
 
 
Table 1: Patient demographics and DXA scan histories. BMI: body mass index. ± Standard 
deviation.  
 Received PTAF  
(n=50) 
Did not receive PTAF 
(n=143) 
Mean age 81 ± 9 82 ± 8 
Mean BMI 25 ± 5 25 ± 6 
Female gender 37 (74%) 102 (71%) 
DXA scan before fracture 5 (10%) 31 (22%) 
DXA scan after fracture 1 (9%) 6 (22%) 
 
Our analysis further showed there was no significant difference in pharmacologic management 
when the patients were stratified according to age group; most of our patients (n=71) were between 
80 and 89 years old (Table 2). 
 
Table 2: PTAF and non-PTAF patients stratified into ten-year age groups. 
Age range (years) Received PTAF 
(n=50) 
Did not receive PTAF 
(n=143) 
60-69 3 (20%) 12 (80%) 
70-79 19 (29%) 47 (71%) 
80-89 17 (24%) 54 (76%) 
90-99 11 (27%) 30 (73%) 
 
FRAX analysis was done on the group of patients that did not receive PTAF in order to quantify 
their risk of future fractures. Our results indicate that the majority of subjects who did not receive 
50 (26%)
143 (74%)
PTAF
No PTAF
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PTAF were at high risk for future fracture (major osteoporotic fracture ≥ 20%, hip fracture ≥ 3%) 
(Tables 3 & 4). 
 
Table 3: FRAX-derived ten-year risk of major osteoporotic fracture in patients who did not receive 
PTAF. 
Ten-year risk of major osteoporotic fracture Did not receive PTAF (n=121) 
Low risk (<20%) 44 
High risk (>20%) 77 
 
 
Table 4: FRAX-derived ten-year risk of hip fracture in patients who did not receive PTAF. 
Ten-year risk of hip fracture Did not receive PTAF (n=121) 
Low risk (<3%) 6 
High risk (>3%) 115 
 
Discussion 
 
Non-traumatic fractures in the elderly are typically due to underlying osteoporosis.14 Uniform 
guidelines for prevention, assessment and management have been developed for this condition 
by various organizations. Results from this study and many others indicate a major need for 
attention to the pharmacological management of this condition.15,16  
 
One main area that can lead to definite improvement in management is the prevention and early 
detection of patients at risk. Deficiency in vitamin D and calcium have long been associated with 
increased risk of fractures.17,18 The addition of these supplements is proven to be beneficial in 
bone health.19-21 This is one of the limitations of our study since there are no records of previous 
vitamin D and calcium supplementation. Further, the serum levels of vitamin D and calcium, at 
the time of presentation, were not reviewed for each patient.  
 
Early diagnosis is another important factor in initiating treatment. DXA-scan measures bone 
mineral density (BMD) and is a major tool used to identify patients with osteopenia or 
osteoporosis.22,23 Unfortunately, the state of West Virginia and many rural areas have limited 
access to DXA scans with only 24 of our 55 counties having this gold standard for 
osteoporosis/osteopenia detection.1 This leaves a large number of rural patients without BMD 
scores, and thus, they are not given pharmacologic treatment. The FRAX analysis is a survey that 
does not require expensive equipment to administer. It has been used as an adjunct to determine 
patient need for pharmacologic treatment. FRAX provides a 10-year fracture risk and can be 
used with or without femoral neck bone mineral density.24  However, current guidelines require 
that the patient has osteopenia demonstrated by DXA scan combined with FRAX results before 
pharmacologic treatment is indicated. Future studies should investigate the initiation of 
osteoporosis treatment using FRAX analysis with and without DXA scan results. 
 
Post fracture management is another area that needs improvement. According to National 
Osteoporosis Foundation, pharmacologic treatment should be started in anyone with history of 
vertebral or hip fracture, patients with T score of ≤ -2.5, patients with osteopenia according to 
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DXA scan or patients with ten year fracture risk assessment ≥ 3% of vertebrae and hip or ≥ 20% 
risk of fracture in other areas including the hip, clinical spine, forearm/wrist or proximal 
humerus.2,25 We found that only 18.6% of patients in our study had a DXA scan prior to their 
fracture, and only 3.6% after their fracture. Once we performed FRAX analysis on our patient 
group (without femoral neck bone mineral density), 54% (n= 77) had greater than 20% risk of 
major osteoporotic fracture and 77% (n= 110) of our patients had over 3% risk of major 
osteoporotic fracture. Findings from this study along with many others indicate under treatment 
in this vulnerable population and the need for attention and review of guidelines in place. 
 
In conclusion, our study demonstrates the under-treatment of clinical osteoporosis and presents 
an opportunity to improve patient care. Using our results as a baseline, we can strive to increase 
the number of patients who initiate PTAF within six months of their events. We have proposed 
to implement a clinical pathway that discharges patients from the hospital with a prescription 
anti-resorptive medication and instructions to follow up with an endocrinologist or primary care 
physician. It is important to encourage patients to follow up with an endocrinologist if they have 
a complicated medical history that disqualifies them for first-line bisphosphonate therapy. In 
addition, a multidisciplinary hip fracture program at Cabell Huntington Hospital is using this 
data to narrow the post fracture pharmacological osteoporosis treatment gap.
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